WORCESTER, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration. Under this agreement, the parties will evaluate the potential utility of RXi’s proprietary rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds. Financial terms of the collaboration were not disclosed. (read more)
Incoming search terms for this article:
- rxi therapeutics
- Formation Of Research Collaboration In The Field Of microRNARXi Pharmaceuticals
- RXi/miRegan therapeutics
- rxi pharmaceuticals microRNA
- RXi miRagen
- Published News Upcoming News Submit a New Story Groups mass effect
- MiRegan boulder
- miragenic pharmaceutical laborotory
- miRagen Therapeutics?country
- miragen pharmaceuticals
Related posts:
- RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics
- RxGen and miRagen Announce Award of NIH-NHLBI SBIR Grant to Fund Advanced Preclinical Studies Evaluating the Role of microRNAs in Cardiac Disease
- Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
- miRagen Looks to Oppurtunities of microRNA Therapeutics
- Alnylam Pharmaceuticals & Regulus Therapeutics in the News
Loading ...
